Table 4. Prognostic role of FGFRs protein expression in 63 MPNST patients.
| Group (63 cases) | Disease free survival | Overall survival | ||
|---|---|---|---|---|
| χ2 | P | χ2 | P | |
| Gender | .101 | .751 | .024 | .878 |
| Age (≥ 40 year, < 40 year) | .362 | .547 | .745 | .388 |
| NF1 type | 16.500 | .000 | 6.547 | .011 |
| Tumor site | 1.393 | .498 | .696 | .706 |
| Tumor size (5, 10) | 2.466 | .291 | 2.360 | .307 |
| AJCC stage | 10.110 | .018 | 7.418 | .060 |
| Radiotherapy | 3.346 | .067 | 1.470 | .225 |
| Chemotherapy | 2.904 | .088 | 1.916 | .166 |
| Surgical type | .002 | .967 | .086 | .770 |
| Recurrence | 26.550 | .000 | 8.174 | .004 |
| Metastasis | 16.189 | .000 | 8.252 | .004 |
| FGFR1 (−/+,++/+++) | .456 | .500 | 6.093 | .014 |
| FGFR1 FISH (−/+) | .046 | .831 | .007 | .935 |
| FGFR2 (−/+,++,+++) | 1.091 | .296 | .105 | .746 |
| FGFR1 combined with FGFR2 | .403 | .818 | 6.215 | .045 |
| FGFR4 (−/+,++/+++) | 4.546 | .033 | 2.311 | .128 |